Program

1st day (19th March)
8:45 -The hall & the reception desk (at 10F lobby) opening

9:30 -Opening address
Dr. Wolfgang Weiss (ex-UNSCEAR Chair)
Overview of this workshop
Dr. Yoshiharu Yonekura (ex- NIRS President, ex-UNSCEAR Chair)

9:45 - 11:45

Morning session
1.1. Dose and Dose-rate Effects
Chairperson: Dr. Ulrike Kulka (BfS)

1M01

Dose- and Dose-Rate Effects of Ionizing Radiation for Cancer Incidence andLife-Shortening.
Dr. Gayle Woloschak (Northwestern University)

1M02

Life span and tumorigenesis in mice exposed to continuous low dose-rate
gamma rays.
Dr. Ignacia Braga-Tanaka (Institute for Environmental Sciences)

1M03

How high can you go, radionuclide therapy is effective at low dose rate.
Dr. Mark Konijnenberg (Erasmus MC)

11:45 - 13:00
13:00 - 15:30

Lunch breakAfternoon session I
1.2. From Mutation to Cancer
Chairperson: Dr. Masako Bando (Kyoto University, Osaka University)

1A11

Overview: The divergence of approaches from molecular biology and macrolevel.
Dr. Masako Bando (Kyoto University, Osaka University)

1A12

Responses to low dose radiation in vivo: DNA damage, aging, and immuneregulation.
Dr. Yi Wang (CNL)

1A13

Dose-rate effects of lymphocyte chromosome aberrations in chronically
irradiated mice after age adjustment.
Dr. Kimio Tanaka (Institute for Environmental Sciences)

1A14

WAM model - a dynamic equilibrium model for the dose-rate effect.
Dr. Yuichi Tsunoyama (Kyoto University)

Panel discussion“Overcome the divergence of approaches of molecularbiology from macro level.”

15:30 - 16:00
16:00 - 18:00

Coffee breakAfternoon session II
1.3. Activities of the Consortium for Medicine, Chemistry and Physics atOsaka University
Chairperson: Dr. Atsushi Shinohara (Osaka University)

Opening
Dr. Atsushi Shinohara (Graduate School of Science, Osaka Univ.)

16:05 - 16:20
1A21

Medicine and science collaborative research for targeted alpha therapy inOsaka University.
Dr. Koichi Fukase (Graduate School of Science, Osaka Univ.)

16:20 - 16:45
1A22

Production and isolation of At-211 for targeted alpha therapy at OsakaUniversity.
Dr. Zijian Zhang (Graduate School of Science, Osaka Univ.)

16:45 - 17:10
1A23
17:10 - 17:35
1A24
17:35 - 18:00
1A25

Radiolabeling of small molecules with astatine(211At) for theranostics.
Dr. Yoshifumi Shirakami (Graduate School of Medicine, Osaka Univ.)
Preparation of novel anticancer drugs using At-211.
Dr. Kazuya Kabayama (Graduate School of Science, Osaka Univ.)
Imaging of the targeted alpha therapy for the clinical application.
Dr. Tadashi Watabe (Graduate School of Medicine, Osaka Univ.)

2nd day (20th March)
9:00 - 11:30

Morning session
2.1. Medical Database
Chairperson: Dr. Nobuyuki Osakabe (Hitachi, Ltd.)

2M01

Biomarkers and radiation therapy for patients with head and neck cancer.
Dr. Pierre Saintigny (Cancer Research Centre of Lyon)

2M02

Present status of patient dose in large part of the world.
Dr. Madan Rehani (MGH, HMS/IAEA)

2M03

Millennial medical record project - Toward establishment of authentic
Japanese version EHR and secondary use of medical data –Dr. Hiroyuki Yoshihara (Kyoto University, University of Miyazaki)

Panel discussion “How can medical database be effectively used in the BER
study and practice?”
Panelist: Dr. Nobuyuki Osakabe (Hitachi, Ltd.) & all speakers

11:30 - 13:00
13:00 - 15:00

Lunch breakAfternoon session I
2.2. Imaging Techniques for Radiotherapy and Cancer diagnosis(Big data and diagnosis, treatment)
Chairperson: Dr. Jun’ichi Kotoku (Teikyo University)

2A11

Potentials of Radiomics in Cancer Treatment.
Dr. Hidetaka Arimura (Kyushu University)

2A12

Imaging database and radiomics.
Dr. Akihiro Haga (Tokushima University)

2A13

Radiomics on MRI field.
Dr. Koji Sakai (Kyoto Prefectural University of Medicine)15:00 - 15:30
15:30 - 17:30

Coffee breakAfternoon session II
2.3. Radiation Biology and Medical Use
Chairperson: Dr. Akihiro Haga (Tokushima University)

2A21

Contribution of biological analysis platform to optimize the medical use ofionizing radiation.
Dr. Ulrike Kulka (BfS)

2A22

Quantitative personalized oncology - Mathematical models for precision
radiotherapy.
Dr. Heiko Enderling (Moffitt Cancer Center)

2A23

Medical radiation protection research strategies in Europe and the role of the
medical physicist in Europe.
Dr. Christoph Hoeschen (Otto-von-Guericke University)

18:00 - 19:30

Poster session

19:30 - 21:30

Reception (Welcome meeting)Room No.406 (4F)

Salon (9F)

3rd day (21st March)
9:00 - 11:30

Morning Session
3.1. Presidential Session: International Cooperation in Biological Effectsof Radiation
Chairperson: Dr. Yoshiharu Yonekura (ex-UNSCEAR Chair)

3M01

Understanding low dose radiation exposure effects : MELODI’s views on
developing international cooperation.
Dr. Jacques Repussard (MELODI)

3M02

Electric Power Research Institute International Dose Effect Alliance.
Dr. Donald A. Cool (EPRI, IDEA)

3M03

Low-Dose Radiobiology Program at Canadian Nuclear Laboratories: Past,
Present and Future.
Dr. Dmitry Klokov (CNL)

3M04

Planning and Acting Network for Low Dose Radiation Research (PLANET) andpromotion for integrated network in Japan.
Dr. Yutaka Yamada / Dr. Yoshiya Shimada (QST, PLANET)

3M05

JSPS committee “multidisciplinary research on the biological effects ofradiation”.
Dr. Takahiro Wada (JSPS committee)

Short talks on each organization / panel discussions

11:30 - 13:00
13:00 - 15:00

Lunch breakAfternoon session I
3.2. Radiation Protection in Medicine
3.2.1. Radiation induced cancer
Chairperson: Dr. Yoshiya Shimada (QST)3A11

Radiation protection in therapy with radiopharmaceuticals.
Dr. Makoto Hosono (Kindai University)

3A12

Experimental evaluation of the carcinogenic effect of carbon ions and neutrons
in children.
Dr. Tatsuhiko Imaoka (NIRS, QST)

3A13Second cancer after radiotherapy.
Dr. Jean-Marc Cosset (Amethyst Group, former ICRP C3 member)

15:00 - 15:30
15:30 - 17:30

Coffee breakAfternoon session II
3.2.2. New medical equipment for less radiation dose
Chairperson: Dr. Makoto Hosono (Kindai University)

3A21

Cancer risk from paediatric CT scanning.
Dr. Elisabeth Cardis (Institut de Salut Global de Barcelona)

3A22

Low-dose CT screening for lung cancer.
Dr. Takeshi Nawa (Hitachi General Hospital)

3A23

Development of low dose diagnostic CT.
Dr. Takashi Tanaka (Canon Medical Systems)

17:30 - 17:45

Closing Remarks